Navigation Links
Independent Laboratory Testing Shows BioNeutral's Hospital Grade Ygiene(TM) Eliminates Aspergillus Niger (Black Mold) Spores
Date:7/7/2009

NEWARK, N.J., July 7 /PRNewswire-FirstCall/ -- BioNeutral Group, Inc. ("BioNeutral") (OTC Bulletin Board: BONU), a chemical technology-based Life Science company announced today that independent laboratory testing performed by ATS Labs shows that Aspergillus Niger mold spores are completely eliminated by the Company's Ygiene(TM) Hospital Grade antimicrobial in record time.

ATS Labs, using the EPA required Fungicidal Use Dilution test, showed that approximately 2.5 million Aspergillus Niger spores were totally eliminated within two (2) minutes. Aspergillus Niger is a type of black mold spore which is a prolific human heath threatening problem. The spore form of this black mold is particularly difficult to eliminate and total eradication is required in order to alleviate associated health threatening issues.

BioNeutral's Chief Science Officer, Dr. Andy Kielbania, PhD. stated, "These results are particularly important because they both validate our internal lab testing protocols and also confirm the speed, efficacy and power of our Ygiene(TM) antimicrobials. The sporicidal efficacy against Aspergillus Niger (Black Mold) is a key accomplishment for our company." He continued, "These independent lab test results represent a significant achievement. Based upon these results we believe our hospital grade Ygiene(TM) will easily eliminate any health threatening bacteria including very dangerous and difficult to kill antibiotic resistant forms including, Methicillan Resistant Staphylococcus Aureus often referred to as "MRSA", drug resistant Pseudomonas Aeruginosa and the very difficult to eradicate pan resistant Klebsiella Pneumoniae. Obviously the new strain of H1N1 virus (Swine Flu) will not present any problem for our formula to achieve a total Kill in record time."

In an article in Environmental Business International, Inc., The Chelsea Group, an Indoor Air Quality (IAQ) consulting and market research firm, estimates the IAQ market caused by toxic mold to be $2 to $3 billion annually and Anthony Worthan, President and COO of Air Quality Sciences, an IAQ consulting firm in Atlanta, estimates the IAQ market to be growing at an annual rate of 25%.

"These positive independent laboratory results validate that our Hospital Grade formula is now well on its way to becoming the next generation technology in EPA approved disinfectants and sterilants for health care facilities around the world," stated Stephen J. Browand, President and CEO of BioNeutral Group, Inc. "I am confident that our rigorous independent testing program will continue to validate our advanced technology performance with a 100% Total Kill at record speed, while also remaining friendly to people and the environment."

About ATS Labs:

ATS Labs, http://www.ats-labs.com is a leading internationally recognized lab used by the developers and users of antimicrobial products. They provide comprehensive antimicrobial service and their superior client service and scientific data have earned them a distinguished record of acceptance with regulatory agencies in the U.S., Canada and the world.

About BioNeutral Group, Inc.

Headquartered at the New Jersey Institute of Technology/EDC in Newark, New Jersey, BioNeutral Group, Inc., is a chemical technology-based Life Science company that intends to commercialize a combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene(TM) and Ogiene(TM), which are eco-friendly and include natural and common ingredients which are found in baby products and in every day foods. The Company has combined these widely-used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications.

More information about the Company may be found at www.bioneutralgroup.com

Forward-Looking Statements

BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene(TM) and are not yet available for sale in the United States.

Contact Information

    BioNeutral Group Inc.
    Stephen J. Browand, President and CEO
    steve@bioneutralgroup.com

    Investor Relations
    Aimee Boutcher
    973 239-2878
    aboutcher@aol.com


'/>"/>
SOURCE BioNeutral Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Independent Health to Begin Offering Its Members Vitamins, Supplements and Natural Products
2. New Technology Assists Independent Seniors
3. Helping Dad Stay Independent: The Best Fathers Day Gift for an Aging Parent - A Checklist from Dr. Dan Tobin, Founder and CEO of Care Support of America
4. Three Independent Proxy Advisory Firms Support Stockholder Nominees in Amylin Proxy Fight
5. Support Bristols Highly Qualified Independent Nominees for Advocat Board
6. Gentiva(R) Health Services Receives Nasdaq Notification Regarding Independent Director Requirement
7. Important Data Presented on Independent Predictors of Mortality in Patients With Idiopathic Pulmonary Fibrosis
8. New Organization Formed To Save Independent Medical Equipment Suppliers
9. Super Lice Repelled by All-Natural Products First Ever Independent Study Shows
10. Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan
11. Vigilan Honors National Nurse Week in Assisted Living, Independent Living and Dementia Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... is actively feeding the Frederick area economy by obtaining investment capital for emerging ... the past 2½ years that have already resulted in more than a million ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a provider of ... other difficult to transfect cells, announces its launch of the PluriQ™ G9™ Gene ... System is a complete system for culturing and transfecting human pluripotent stem ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: